109 filings
Page 4 of 6
6-K
3yoant5jxo
22 Sep 20
Zai Lab Announces Pricing of Hong Kong Secondary Listing
8:08am
6-K
tn0tqbqi07s2 kubxci5
21 Sep 20
Current report (foreign)
4:15pm
6-K
akup3ml
16 Sep 20
Zai Lab Launches Hong Kong Secondary Listing
7:18am
6-K
9ownarld7e 97
11 Sep 20
Current report (foreign)
8:16am
6-K
66z8t6
11 Sep 20
Zai Lab Limited Supplemental and Updated Disclosures
8:09am
6-K
lpt5pj a2z5
10 Sep 20
Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China
7:35am
6-K
lp94fjwd
4 Sep 20
Current report (foreign)
4:01pm
6-K
042m6p222j3zlnnwgn9n
17 Aug 20
Zai Lab Appoints F. Ty Edmondson as Chief Legal Officer
7:35am
6-K
v8vzpibl v6ogf8dc
13 Aug 20
Current report (foreign)
7:30am
6-K
vylrg 233vc19a
10 Aug 20
Form 6-K for Zai Lab Limited - August 7, 2020
12:00am
6-K
76ozih8izj2rq3xoqd3
20 Jul 20
China NMPA Accepts NDA Submission of Ripretinib for Advanced Gastrointestinal Stromal Tumor
7:35am
6-K
jrlu 427efg1
7 Jul 20
Turning Point Therapeutics and Zai Lab Announce
7:35am
6-K
stnmm7ydg d31
13 May 20
China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
10:22am
6-K
oe2l2n
8 Apr 20
Zai Lab obtains rights to develop and exclusively commercialize REGN1979 in oncology in mainland China, Hong Kong, Taiwan and Macau
6:03am
6-K
f08el2ezpetiw xgws2v
19 Mar 20
Current report (foreign)
7:53am
6-K
3o08jqpr3wz
16 Mar 20
Zai Lab Announces Acceptance of sNDA Submission of ZEJULA® (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China by the NMPA
7:39am
6-K
op0strkns 8y
27 Jan 20
Zai Lab Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Greenshoe Option
4:41pm
6-K
mn31ml1zd9f0
23 Jan 20
Zai Lab Announces Pricing of Public Offering of American Depositary Shares
6:08am
6-K
7kdl35jn5y
22 Jan 20
Current report (foreign)
11:58am
6-K
8mzuo
21 Jan 20
Current report (foreign)
5:31pm